Home » FDA Eases Trial Requirements for Drugs to Treat Alzheimer’s
FDA Eases Trial Requirements for Drugs to Treat Alzheimer’s
The FDA is broadening the allowed participant pool and relaxing MRI requirements for Alzheimer’s drug trials in response to recommendations from a stakeholder working group.
Clinical Trials Advisor
Clinical Trials Advisor
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May